Gufic Biosciences appoints Dr Kathiresan Rajasekar as President - International Business, Senior Management Personnel
Karnataka: Gufic Biosciences has announced the appointment of Dr Kathiresan Rajasekar as President – International Business, Senior Management Personnel of the Company.
"We wish to inform you that on the basis of recommendation of Nomination & Remuneration Committee, the Board of Directors vide Circular Resolution passed today i.e. January 14, 2025 has approved the appointment of Dr Kathiresan Rajasekar as President – International Business, Senior Management Personnel of the Company with effect from January 14, 2025," the Company stated in a BSE filing.
Dr. Kathiresan Rajasekar holds a Doctorate and M.Phil in Management, a Diploma in Intellectual Property Rights (IPR), an MBA specializing in International Business, and a B.Sc. in Pharmaceutical Chemistry.
With over 28 years of experience in the pharmaceutical industry, he is a seasoned Techno‐ Commercial professional and accomplished Top Management leader. Dr. Rajasekar has a proven track record of driving startups to sustained success, managing P&L for businesses exceeding $125 million, and achieving consistent year‐on‐year growth across diverse commercial functions, including Sales, Marketing, and Business Development. He has extensive hands‐on experience in establishing global injectable manufacturing facilities and specializes in Techno‐Commercial operations for regulated markets.
His comprehensive insights are further enriched by his global perspective, gained through living and working in various countries and extensive travel to over 128 nations. Dr. Rajasekar has held leadership roles in renowned organizations, including serving as Associate Director, International Business at Emcure Pharmaceuticals Limited, and as Senior Country Manager/Deputy General Manager at IPCA Laboratories Limited. His unique blend of technical expertise, strategic vision, and international exposure positions him as a leader adept at navigating both domestic and global pharmaceutical markets.
Read also: Gufic Biosciences unveils Botulinum Toxin Type A injection 'Zarbot' in India
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.